Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of November 2025. The filing details a share repurchase executed on November 5, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share repurchase rather than operational financial performance (revenue, profit, or cash flow).
- Shares Purchased (Nov 5, 2025): 170,000 ordinary shares.
- Price Range: Lowest 1,779.00p; Highest 1,798.00p.
- Volume-Weighted Average Price (VWAP): 1,789.04p.
- Programme Progress: Since September 30, 2025, the Company has purchased an aggregate of 7,819,000 ordinary shares.
- Treasury Shares Held: 255,283,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,060,139,755 ordinary shares.
- Total Voting Rights: 4,060,139,755.
- Treasury Voting Percentage: 6.29% of total voting rights.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or earnings) against prior periods. The material change reported is the reduction in the number of shares in issue and the increase in treasury shares held by the Company following the November 5 transaction. The aggregate buyback volume has increased by 170,000 shares since the last reported update within the current programme period.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, earnings outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the Company's 2024 Annual Report on Form 20-F and Q3 2025 Results. No specific new risks or contingencies were disclosed in this transaction report.
Important Facts for Investor Verification
- Verify the total number of shares in issue (4,060,139,755) to ensure accurate calculation of ownership percentages under Disclosure Guidance and Transparency Rules.
- Confirm the 6.29% voting rights held in treasury, which do not carry voting rights.
- Note that the buyback is executed via a non-discretionary agreement with BNP Paribas SA, limiting the Company's ability to alter the programme parameters unilaterally.
- Review the 2024 Form 20-F and Q3 2025 Results for the full context of risk factors referenced in the cautionary statement.